Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Dementia 2019

Sessions/Tracks

Track 1: Managing Dementia

Dementia is the term used to describe the symptoms of several conditions that affecting the brain. The commonly seen condition is Alzheimer’s, and other includes Parkinson's disease. Symptoms seen at early stages are personality changes, withdrawal, memory loss, confusion and apathy. Early diagnosis helps with providing early treatment, support and planning. Medications might help with some symptoms of dementia, but no permanent cure.

Majority of people with dementia are above age 65, the condition is not normal for all older people. The occurrence of dementia gets high with age, but it’s not given that an older person will develop it. While only 1-in-4 people with Alzheimer’s disease or Dementia has been diagnosed. Few more things we need to know about vascular dementia, Dementia with lewy bodies, Fronto-temporal dementia, Rarer causes of dementia, Creutzfeldt-Jakob disease, HIV-related cognitive impairment, Mild cognitive impairment.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

American Brain Tumor Association; American Cancer Society; American Parkinson Disease Association; American RSD Hope Organization and American Sleep Apnea Association; American Speech-Language-Hearing Association; Autism Network International; Autism Science Foundation and Autism Society of America; Autism Society of America Foundation

European Union and UK:

Alzheimer's & Dementia Help Germany; Alzheimer Europe; German Alzheimer Society; Federazione Alzheimer Italia; Alzheimer's & Dementia Help; Giovanni B Frisoni; Actifcare; Association France Alzheimer

Asia-Pacific and Middle East:

Alzheimer's & Dementia Help; Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya; Japan - Dementia Friendly Communities; Alzheimer's Association Japan; Dementia care in Japan; China Alzheimer's Project; Alzheimer associations China

Persons with dementia have multiple psychological feature deficits that include each memory impairment, that affects the flexibility to find out new info or recall information previously learned, and one or additional of the subsequent symptoms-aphasia, apraxia, agnosia, or executive dysfunction-such that the psychological feature deficits negatively have an effect on social or activity functioning with a big decline in previous talents. Additionally, persons with dementia typically suffer from comorbid conditions that additional complicate care and impede best outcomes. Therefore, developing caregiving methods people with dementia is urgent, given this increasing prevalence and therefore the associated burden that dementia places not only on the individuals, however on the caregivers, relations, and therefore the resources of the health care system. Conventional views bearing on geriatric nursing typically paint an image of the care as being slow paced certain and less demanding than acute care. However, care of the aged, and particularly those with dementia, is usually complicated, unpredictable, and unstable.

This session includes Education and training of medical professionals, Care and quality of life, Person centered care, Cognitive training, Support and training for informal and professional careers, Putting scientific knowledge into practice, Non-pharmacological Interventions, Functional foods, Art, music and life style.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

American Stroke Association; Brain Injury Association of America; Brain Injury Resource Center; Cerebral Palsy Foundation and CHADD; Childhood Brain Tumor Foundation; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation; Lewy Body Dementia Association

European Union and UK:

France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain; Synapsis Foundation; Switzerland - National Dementia Strategies; Czech Alzheimer Society; Alzheimer Austria

Asia-Pacific and Middle East:

Alzheimer Society of Manitoba; Memory Makers for Alzheimer's; EMDA; Thailand Honorary Consulate; Saudi Alzheimer’s disease Association; Dementia Friends HK; Alzheimer's Disease Association of the Philippines; Dementia Society of the Philippines; Federation Member Associations

Track 3: Alzheimer’s Disease Imaging

Scientists look at the brain’s grey matter when investigating about Alzheimer’s disease. A fresh study, found that degenerating white matter in the brain could be an early indicator of disease. A study was published in Radiology which concludes that white matter plays an important role in how the disease strikes and progresses. Abnormal deposits of proteins that form amyloid plaques and tau tangles all over the brain in Alzheimer’s disease. It can also be characterized by shrinkage of brain tissues due to neurons loss.

This session includes Amyloid and Tau imaging, Imaging animal models, Imaging and genetics, New methods in imaging, Structural and functional MRI, Positron emission tomography, MR spectroscopy, EEG and brain mapping, SPECT imaging, Imaging correlates of clinical, cognitive and biomarker variables.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Lewy Body Dementia Association; Jain Foundation and John Douglas French Alzheimer's Foundation; Intractable Childhood Epilepsy Alliance; Huntington's Disease Society of America; Michael J. Fox Foundation for Parkinson's Research; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation

European Union and UK:

Federazione Alzheimer Italia; Alzheimer's & Dementia Help; Giovanni B Frisoni; Association France Alzheimer; France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain

Asia-Pacific and Middle East:

Alzheimer And Related Dementia Society Nepal; Mental Illness Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata; Alzheimer's & Dementia Help; Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya

Track 4: Causes and Prevention of Alzheimer’s

Alzheimer's is caused by brain cell death. It is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer's, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called tau.

Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015, past results shown 35.66 million population lived with dementia  worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

In this track we can discuss on Neurological changes in brain, Amyloid protein, Genetic associations and susceptibility genes, Role of Apo lipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Epidemiology and prevalence, Histone modification, DNA methylation, Alzheimer’s disease prevention.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Alternating Hemiplegia of Childhood Foundation; Alzheimer's Drug Discovery Foundation; Alzheimer's Association and Alzheimer's Foundation of America; American Association of Health and Disability; American Autoimmune Related Diseases Association; American Behcet's Disease Association and American Brain Coalition; American Brain Tumor Association; American Cancer Society; American Headache Society Committee for Headache Education; American Heart Association

European Union and UK:

Lowe Syndrome Association; The Alzheimer Society of Ireland; Alzheimer Society London; Alzheimer Society Middlesex; Alzheimer's & Dementia Help Germany; Alzheimer Europe; German Alzheimer Society; Federazione Alzheimer Italia

Asia-Pacific and Middle East:

Dementia Friends HK; Alzheimer's Disease Association of the Philippines; Dementia Society of the Philippines Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya; Japan - Dementia Friendly Communities; Grey zone - Coping with senility in Japan

Track 5: Alzheimer’s Disease Diagnosis and Symptoms

Alzheimer's is caused by brain cell death. It is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer's, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called tau.

Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015,past results shown 35.66 million population  lived with dementia  worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

In this track we can discuss on Neurological changes in brain, Amyloid protein, Genetic associations and susceptibility genes, Role of Apo lipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Epidemiology and prevalence, Histone modification, DNA methylation, Alzheimer’s disease prevention.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Acoustic Neuroma Association; Aicardi Syndrome Foundation; Alternating Hemiplegia of Childhood Foundation; Alzheimer's Drug Discovery Foundation; Alzheimer's Association and Alzheimer's; Foundation of America; American Association of Health and Disability; American Autoimmune Related Diseases Association; American Behcet's Disease Association and American Brain Coalition

European Union and UK:

ALS Association and ALS Therapy Development Institute; Attention Deficit Disorder; Association and Autism National Committee; Carter Center for Brain Research in Holoprosencephaly; Lowe Syndrome Association; The Alzheimer Society of Ireland; Alzheimer Society London; Alzheimer Society Middlesex

Asia-Pacific and Middle East:

International Radio Surgery Association; Asian Society Against Dementia; Alzheimer And Related Dementia Society Nepal; Mental Illness; Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata

Track 6: Alzheimer’s Disease Pathophysiology and Disease Mechanisms

Alzheimer’s disease is a progressive dementia with loss of neurons and the presence of two main microscopic neuropathological hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles. Early onset AD, a rare familial form, is caused due to mutation of one out of three genes: (amyloid precursor protein), (presenilin 2) or (presenilin 1).  Sporadic form occurs usually after age of 65 and accounts for most cases; it most likely results from a combination of genetic and influence of environment. Confirmed risk factors for sporadic AD are age and the presence of the E4 allele of (Apo lipoprotein E). Amyloid plaques comprise mainly of the neurotoxic peptide amyloid (Aβ, Abeta), cleaved sequentially from a larger precursor protein (APP) by two enzymes: β-secretase (also called BACE1) and γ-secretase (comprising four proteins, presenilin is one of them). If APP is first cleaved by the enzyme α-secretase rather than β-secretase then Aβ is not formed. Neurofibrillary tangles comprise mainly of the protein tau which binds with microtubules, which facilitating the neuronal transport system. Tau uncoupling from microtubules and aggregation into tangles inhibits transport and results in disassembly of microtubule. Phosphorylation of tau might have an important role in this. Selective vulnerability of neuronal systems such as the cholinergic, serotonergic, and noradrenergic and glutamatergic systems form the basis of current rational pharmacological treatment.

This session includes Aging, Prions and Alzheimer’s disease, Cellular signaling and cell to cell transmission, Oxidative damage and mitochondrial dysfunction, Autoimmunity in Alzheimer’s, Blood-brain barrier and transport, Neurogenesis and stem cells and Cell death.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

American Stroke Association; Brain Injury Association of America; Brain Injury Resource Center; Cerebral Palsy Foundation and CHADD; Childhood Brain Tumor Foundation; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation; Lewy Body Dementia Association

European Union and UK:

France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain; Synapsis Foundation; Switzerland - National Dementia Strategies; Czech Alzheimer Society; Alzheimer Austria

Asia-Pacific and Middle East:

Alzheimer Society of Manitoba; Memory Makers for Alzheimer's; EMDA; Thailand Honorary Consulate; Saudi Alzheimer’s disease Association; Dementia Friends HK; Alzheimer's Disease Association of the Philippines; Dementia Society of the Philippines; Federation Member Associations

Track 7: Neurodegenerative Diseases

Neurodegenerative diseases consist of wide range of disorders, characterized by the progressive degeneration or death of nerve cells. It affects nerve tissue and causes different neuropsychological manifestations as well. It is an umbrella term for a range of conditions which particularly affect the neurons in the human brain.

Genetic and environmental factors have been shown to play a vital role in the development of neurodegenerative diseases. Age is one of the major risk factors that is common between all types of neurodegenerative disease as it progresses at older ages commonly.

  • Cognition
  • Multiple Sclerosis
  • Parkinson's disease
  • Huntington's disease
  • Neurovascular Dysfunction and Neurodegeneration

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Lewy Body Dementia Association; Jain Foundation and John Douglas French Alzheimer's Foundation; Intractable Childhood Epilepsy Alliance; Huntington's Disease Society of America; Michael J. Fox Foundation for Parkinson's Research; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation

European Union and UK:

Federazione Alzheimer Italia; Alzheimer's & Dementia Help; Giovanni B Frisoni; Association France Alzheimer; France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain

Asia-Pacific and Middle East:

Alzheimer And Related Dementia Society Nepal; Mental Illness Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata; Alzheimer's & Dementia Help; Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya

Track 8: Vascular Dementia

Vascular dementia, otherwise called multi-infarct dementia is the second most basic reason for dementia in more seasoned individuals. Since it has a lower profile than Alzheimer's, many individuals don't speculate vascular dementia when neglect ends up noticeably hazardous. It's additionally hard to analyze so it's hard to know precisely what number of individuals experience the ill effects of vascular dementia. Current evaluations credit 15% to 20% of dementia cases in more established grown-ups to vascular dementia. Vascular dementia happens when vessels that supply blood to the cerebrum wind up noticeably blocked or limited. Strokes happen when the supply of blood conveying oxygen to the mind is suddenly cut off. Be that as it may, not all individuals with stroke will create vascular dementia. Vascular dementia can happen after some time as "noiseless" strokes heap up. Frequently, vascular dementia attracts regard for itself just when the effect of such many strokes means noteworthy handicap. Staying away from and controlling danger factors, for example, diabetes, hypertension, smoking, and elevated cholesterol can help check the danger of vascular dementia.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

American Stroke Association; Brain Injury Association of America; Brain Injury Resource Center; Cerebral Palsy Foundation and CHADD; Childhood Brain Tumor Foundation; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation; Lewy Body Dementia Association

European Union and UK:

France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain; Synapsis Foundation; Switzerland - National Dementia Strategies; Czech Alzheimer Society; Alzheimer Austria

Asia-Pacific and Middle East:

Alzheimer Society of Manitoba; Memory Makers for Alzheimer's; EMDA; Thailand Honorary Consulate; Saudi Alzheimer’s disease Association; Dementia Friends HK; Alzheimer's Disease Association of the Philippines; Dementia Society of the Philippines; Federation Member Associations

Track 9: Alzheimer’s Clinical Trials and Studies

Clinical trials are inquired about examinations led in individuals to decide if medicines are protected and viable. Without clinical research and the assistance of human volunteers, there can be no better medications, no counteractive action and no cure for Alzheimer's ailment.

Clinical trials are occasionally alluded to as clinical examinations; the terms are frequently utilized reciprocally, yet there are unobtrusive contrasts between them. Clinical trials test new intercessions or medications to avoid, recognize or treat infection. A clinical report is any sort of clinical research including individuals, paying little heed to whether it is trying an intercession. Clinical examinations can likewise take a gander at different parts of care, for example, enhancing personal satisfaction.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Acoustic Neuroma Association; Aicardi Syndrome Foundation; Alternating Hemiplegia of Childhood Foundation; Alzheimer's Drug Discovery Foundation; Alzheimer's Association and Alzheimer's; Foundation of America; American Association of Health and Disability; American Autoimmune Related Diseases Association; American Behcet's Disease Association and American Brain Coalition

European Union and UK:

ALS Association and ALS Therapy Development Institute; Attention Deficit Disorder; Association and Autism National Committee; Carter Center for Brain Research in Holoprosencephaly; Lowe Syndrome Association; The Alzheimer Society of Ireland; Alzheimer Society London; Alzheimer Society Middlesex

Asia-Pacific and Middle East:

International Radio Surgery Association; Asian Society Against Dementia; Alzheimer And Related Dementia Society Nepal; Mental Illness; Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata

Track 10: Therapeutic Targets and Mechanisms for Treatment

Alzheimer's disease is a progressive neurodegenerative disease that is characterized histopathologically by the presence of plaques, mainly composed of Abeta amyloid and the tangles, mainly composed of hyper phosphorylated tau. To date, there is no treatment that can reverse the disease, and all the current therapeutics is directed to cope with the symptoms of the disease. Here we describe the efforts dedicated to attack the plaques and, in more detail, the process of neurofibrillary degeneration, linked to the presence of the hyper phosphorylated microtubule associated protein tau. We have identified the different putative targets for therapeutics and the current knowledge on them.

Treatment for Alzheimer's disease is entering a new and exciting phase, with several new drugs beginning clinical trials. Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. There are several different theories underlying the current efforts, and these are briefly reviewed. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area. It is yet unclear which, if any of these approaches will be successful, but the high level of activity in each of these three fields provides some hope that an effective treatment for Alzheimer's disease is on the horizon.

This session includes Abeta, truncated and pGlu-Abeta, Immunotherapy, Neurotransmitter-based targets, Anti-inflammatory targets, Nanotechnology, Anti-oxidants, Neurotrophic factors, Protein aggregation, Deep brain stimulation, Misfolding and chaperones, Gene therapy, Drug-delivery systems.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Acoustic Neuroma Association; Aicardi Syndrome Foundation; Alternating Hemiplegia of Childhood Foundation; Alzheimer's Drug Discovery Foundation; Alzheimer's Association and Alzheimer's; Foundation of America; American Association of Health and Disability; American Autoimmune Related Diseases Association; American Behcet's Disease Association and American Brain Coalition

European Union and UK:

ALS Association and ALS Therapy Development Institute; Attention Deficit Disorder; Association and Autism National Committee; Carter Center for Brain Research in Holoprosencephaly; Lowe Syndrome Association; The Alzheimer Society of Ireland; Alzheimer Society London; Alzheimer Society Middlesex

Asia-Pacific and Middle East:

International Radio Surgery Association; Asian Society Against Dementia; Alzheimer And Related Dementia Society Nepal; Mental Illness; Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata

Track 11: Animal Models and Translational Medicine

Animal models for Alzheimer’s disease it is important to think about the human phenotype and what is being modeled in terms of the animal phenotype. The moderator, Bradley Hyman, professor of neurology at Harvard Medical School, said that animal models of Alzheimer’s disease, based on the genetics of the disease and the closely related frontotemporal dementia, replicate at least some of the pathology. Researchers have been successful at modeling very specific aspects of Alzheimer’s disease in the mouse (e.g., plaques, tangles). Although these are incomplete models of the human disease, they have been well received in the field as potentially relevant models for use in drug discovery.

Patients with Alzheimer’s disease will display both amyloidopathy and tauopathy; however, scientists often focus, in a reductionist way, on one or the other in an animal model. A participant added that even though the anatomy in the mouse is different than the human, mutant tau mice are relatively good models in that they recapitulate tau-dependent neurodegeneration. This has led many companies to focus on antibodies that block tau-dependent neurodegeneration in these mouse models.

This session includes Transgenic models, Pharmacological and lesion models, Natural and semi natural models, Primate models, Zebra fish models, Animal models of human cognitive aging, Development of new animal models, Genetics of translational models, Protein-protein interactions, Ethical issues with animal models.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Alternating Hemiplegia of Childhood Foundation; Alzheimer's Drug Discovery Foundation; Alzheimer's Association and Alzheimer's Foundation of America; American Association of Health and Disability; American Autoimmune Related Diseases Association; American Behcet's Disease Association and American Brain Coalition; American Brain Tumor Association; American Cancer Society; American Headache Society Committee for Headache Education; American Heart Association

European Union and UK:

Lowe Syndrome Association; The Alzheimer Society of Ireland; Alzheimer Society London; Alzheimer Society Middlesex; Alzheimer's & Dementia Help Germany; Alzheimer Europe; German Alzheimer Society; Federazione Alzheimer Italia

Asia-Pacific and Middle East:

Dementia Friends HK; Alzheimer's Disease Association of the Philippines; Dementia Society of the Philippines Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya; Japan - Dementia Friendly Communities; Grey zone - Coping with senility in Japan

Track 12: Recent Studies & Case Reports

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several etiologies of which Alzheimer’s disease (AD) is the most common.

Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuro-inflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

 Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

5th International Conference on Neuro-Oncology and Brain Tumor, February 27-28, 2019 Seoul, South Korea; 8th International Conference on Brain Injury and Neuroscience, March 14-15, 2019 Paris, France; CPD Accredited Annual Congress on Neurology & Neuroscience, March 14-15, 2019 Paris, France; 5th International Conference on Spine and Spinal Disorders, April 25-26, 2019 Rome, Italy; 9th International Conference on Addictive Disorders and Alcoholism, June 17-18, 2019 Brisbane, Australia; 32nd European Neurology Congress, July 22-24, 2019 London, UK; American Neuroscience and Neurosurgery Congress, June 21-22, 2019 Ottawa, Canada; World Congress on Advances in Brain Injury, October 21-22, 2019 Tokyo, Japan; 26th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences, October 28-29, 2019 Abu Dhabi, UAE

Related Association:

USA and Canada:

Lewy Body Dementia Association; Jain Foundation and John Douglas French Alzheimer's Foundation; Intractable Childhood Epilepsy Alliance; Huntington's Disease Society of America; Michael J. Fox Foundation for Parkinson's Research; Children's Hemiplegia and Stroke Association; Christopher and Dana Reeve Foundation

European Union and UK:

Federazione Alzheimer Italia; Alzheimer's & Dementia Help; Giovanni B Frisoni; Association France Alzheimer; France - Dementia Friendly Communities; Alzheimer Society of Spain; Alzheimer Care in Spain

Asia-Pacific and Middle East:

Alzheimer And Related Dementia Society Nepal; Mental Illness Dementia and Family in China; Alzheimer Society of B.C.; Grey zone - Coping with senility in Japan; ARDSI Kolkata; Alzheimer's & Dementia Help; Dementia Caregiver Resources across India; Dementia Bangalore; Alzheimer's Disease – Aarogya

 

About Conference


Conference Series LLC LTD welcomes every one of the members from everywhere throughout the world to go to the Dementia gathering which is held amid October 29-31, 2018 Valencia, Spain. The principle subject of our meeting is "Investigating the Challenges and Excellence in Dementia Research" which covers extensive variety of basically critical sessions. This meeting manages the ebb and flow consider improvements in the field of Dementia and about the new treatment techniques which are contrived by researchers to treat different maladies in less demanding way. This meeting goes about as a best stage for participants to find out about the current patterns in Dementia innovative work.

Dementia gathering will concentrate on the most recent and energizing developments in every aspect of Dementia consider which offers an interesting open door for agents over the globe to meet, organize, and see new logical advancements. The three days gathering incorporates workshops, symposiums and exceptional keynote sessions led by famous and eminent speakers who exceed expectations in the field of dementia This Worldwide Dementia Meeting likewise energizes the dynamic support of youthful understudies, forthcoming specialists and growing researchers as we are facilitating Poster Award Competition and Young Research Forum at the gathering setting.

Target Group of onlookers:

  • Neurologists and Executives
  • Physicians
  • Neuroscientists
  • Specialists
  • researchers
  • Health mind experts
  • Professors
  • Industrial Specialists
  • Neurosurgeons
  • Psychiatrist
  • Nutritional Researchers
  • Lecturers and Understudies from the scholarly world in the investigation of Dementia
  • Students from the scholarly community in the examination of Neurology

Alzheimer Association & Societies around the Globe

  • Alzheimer's Australia
  • Albanian Alzheimer Society
  • Association de Lucha contra el Mal de Alzheimer
  • Foundation Alzheimer Aruba (FAA)
  • Alzheimer's Australia
  • Alzheimer Austria
  • Alzheimer Support Group
  • Alzheimer Society of Bangladesh
  • Barbados Alzheimer's Association Inc.
  • Alzheimer’s and Dementia Association of The Cayman Islands
  • Ligue National Alzheimer Liga
  • Alzheimer's Family Support Group
  • Association Bolivian de Alzheimer y Otras Dementias
  • FEBRAZ - Federico Brasilia de Associaçãoes de Alzheimer
  • Corporation Alzheimer Chile
  • Alzheimer's disease Chinese
  • Alzheimer Association & Societies in Canada

 

 

Market Analysis

It is our pleasure to welcome you to the Dementia 2018 to be held in Frankfurt, Germany from November 14-15, 2019.

Dementia is general term for memory misfortune and other intellectual capacities sufficiently genuine to meddle with everyday life. Alzheimer's illness represents 60 to 80 percent of dementia cases.

This gathering will build information, offer help, help learning and enable families and carers to search out relevant administrations for their adored one and to build up the most ideal home condition to help recuperation from this mind boggling and decimating maladies.

The global Alzheimer’s Disease (AD) market worth $2.9Bn in 2016 is set to reach $14.8Bn, rising at a Compound Annual Growth Rate (CAGR) of 17.5%, across the 7MM by 2026 according to Global Data, a recognized leader in providing business information and analytics

Alzheimer's disease is the most common form of dementia. The proportions of those with different forms of dementia can be broken down as follows:

Alzheimer's disease: 62%

Vascular dementia: 17%

Mixed dementia: 10%

Lewy-body dementia: 4%

Fronto-temporal dementia: 2%

Parkinson's dementia: 2%

Other: 3%

 

Why Frankfurt??

Frankfurt, a central German city on the river Main, is a major financial hub that's home to the European Central Bank. Frankfurt is located on both sides of the Main River, south-east of the Taunus mountain range. The southern part of the city contains the Frankfurt City Forest, Germany's largest city forest. The city area is 248.31 km2 (95.87 sq mi) and extends over 23.4 km (14.54 mi) east to west and 23.3 km (14.48 mi) north to south.

According to the study in Frankfurt Osteoporosis is estimated to affect 200 million women across the world. In Germany, the prevalence of this chronic disease among people aged 50 years and older is around 15%. In recent decades, several authors have analyzed the impact of osteoporosis on the risk of cognitive decline, but, most of these studies have been conducted outside Europe. The goal of the present study was to investigate the impact of osteoporosis on the risk of developing dementia in almost 60,000 patients followed for up to 20 years in more than 1,200 general practices in Germany.

Numerous studies have shown that physical exercise seems beneficial in the prevention of cognitive impairment and dementia in old age. Now researchers at Goethe University Frankfurt have explored in one of the first studies worldwide how exercise affects brain metabolism.

 

Why to attend???

According to WHO 47.5 million people have dementia and every year 7.7 million new cases are appearing. By 2030 total cases of dementia is projected to be 75.6 million and almost triple by 2050 to 135.5 million. Alzheimer’s disease contributes 60-70 % of cases in dementia and second most common condition of dementia is vascular dementia which contributes 20% of cases all over the world. Total estimated cost of dementia is 818 billion US $ in 2015.

A great opportunity to network with your peers from academia and industry.

At the Dementia conferences and from the eminent people speech, you can update your knowledge about current situation of Dementia research and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Dementia fields are hallmarks of this conference.

 

Conference Highlights:

Managing Dementia

Care Practice and Awareness

Alzheimer’s Disease Imaging

Causes and Prevention of Alzheimer’s

Alzheimer’s Disease Diagnosis and Symptoms

Alzheimer’s Disease Pathophysiology and Disease Mechanisms

Neurodegenerative Diseases

Vascular Dementia

Alzheimer’s Clinical Trials and Studies

Therapeutic Targets and Mechanisms for Treatment

Animal Models and Translational Medicine

Recent Studies & Case Reports

 

Alzheimer Association & Societies around the Globe:

Alzheimer's Australia

Albanian Alzheimer Society

Association de Lucha contra el Mal de Alzheimer

Foundation Alzheimer Aruba (FAA)

Alzheimer's Australia

Alzheimer Austria

Alzheimer Support Group

Alzheimer Society of Bangladesh

Barbados Alzheimer's Association Inc.

Alzheimer’s and Dementia Association of The Cayman Islands

Ligue National Alzheimer Liga

Alzheimer's Family Support Group

Association Bolivian de Alzheimer y Otras Dementias

FEBRAZ - Federico Brasilia de Associaçãoes de Alzheimer

Corporation Alzheimer Chile

Alzheimer's disease Chinese

Alzheimer Association & Societies in Canada

 

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

 

 

Past Conference Report

Dementia 2018

Dementia 2018 Report

The 12th International conference on Alzheimer’s Disease & Dementia, hosted by Conference series llc LTD was successfully held during October 29-31, 2018 in Valencia, Spain. The conference highlighted the theme “Investigating the Challenges and Excellence in Dementia Research”. The conference was successful in gathering eminent speakers from various reputed organizations and their paramount talks enlightened the gathering.

The pragmatic meet organized by CONFERENCE SERIES llc LTD received a generous response from the Editorial Board Members of CONFERENCE SERIES llc LTD Journals as well as expertise from academia, talented researchers and young student community. Researchers and students who attended from different parts of the world made the conference one of the most successful and productive events in 2018 from CONFERENCE SERIES llc LTD. The conference was marked by the presence of renowned Speakers, Young Researchers, Students and Business Delegates driving the Three-day event into the path of success with thought-provoking keynote and plenary presentations.

The highlights of the meeting where the keynote lectures from

  • Petr Zach, Charles University, Czech Republic
  • Magdalena Turek, Care Homes Zapiecek, Poland
  • T Y Chang, Geisel School of Medicine, USA
  • Catherine Chang, Geisel School of Medicine, USA
  • Mourad Tayebi, Western Sydney University, Australia

All the above-mentioned Honourable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Moderator Dr. Gabriel González Pavón, Oncovision, Spain and Petr Zach, Charles University, Czech Republic for his remarkable contribution towards smooth functioning at Dementia 2018. The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

Alzheimer’s Disease: Diagnosis and Symptoms | Managing Dementia | Care Practice and Awareness | Alzheimer’s Disease Imaging | Causes and Prevention of Alzheimer’s | Alzheimer’s disease Pathophysiology and Disease Mechanisms | Amyloid Protein in Alzheimer’s and Dementia | Geriatrics Dementia and Cognitive Disorder | Therapeutic Targets and Mechanisms for Treatment | Animal Models and Translational Medicine | Vascular Dementia | Alzheimer’s disease and Dementia | Traumatic Brain Injury | Dementia with Lewy Bodies  | Alzheimer’s Clinical Trials and Studies

 To share your views and research, please click here to register for the Conference.

 CONFERENCE SERIES llc LTD would like to convey a warm gratitude to all OCM and Keynote Speakers of Dementia 2018 Conference.

Dementia 2018 Conference witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Alzheimers disease and Dementia. The event enlightened various areas of Alzheimers disease and Dementia in different fields with plenary lectures from the speakers of various universities and organizations like

  • Xavier López-Gil, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain
  • Emily Gillett, The CareSide, Australia
  • W Kazana, Hirszfeld Institute of Immunology and Experimental Therapy-Polish Academy of Sciences, Poland
  • Shaymaa Abdulghaffar Abdulmalek, Alexandria University, Egypt
  • Muhammad Asif Rasheed, COMSATS University Islamabad, Pakistan
  • Etrat Hooshmandi, Shahid Beheshti University of Medical Sciences, Iran
  • Weonkuu Chung, Kyung Hee University Hospital, South Korea
  • Arooge Shafi, Gosford Private Hospital, Australia
  • Vesna Vuksanovic, University of Aberdeen, UK
  • Zagrebin V L, Volgograd State Medical University, Russia 
  • Soraya L Valles, University of Valencia, Spain

We are obliged to various delegate experts, institutes and other eminent personalities who actively took part in the discussion and meetings. We sincerely thank the Organizing Committee Members for their gracious presence and continuous support towards the success of Dementia 2018 Conference.

With the valuable feedback and generous response received from the participants of the event, CONFERENCE SERIES llc LTD would like to announce the commencement of the 13th International Conference on Alzheimer’s Disease & Dementia, November 14-15, 2019 in Frankfurt, Germany.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date November 14-15, 2019

Speaker Opportunity

Past Conference Report

Supported By

Journals of Alzheimers Disease and Parkinsonism Journal of Neurological Disorders Brain Disorders and Therapy

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner